Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

11.54 -0.62 (-5.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
The 3 Most Promising Biotech Stocks to Own Now
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential. 
Via InvestorPlace
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
The famous growth investor has been making some interesting stock moves lately. 
Via The Motley Fool
The Latest Analyst Ratings for Intellia Therapeutics
Via Benzinga
Cathie Wood's Bullish Stance on Flying Cars: Ark Buys $3.9M Worth of Archer Aviation Shares
Via Benzinga
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge
Via Benzinga
Topics Artificial Intelligence
Barclays Maintains Overweight Rating for Intellia Therapeutics: Here's What You Need To Know
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Preview: Intellia Therapeutics's Earnings
Via Benzinga
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite stocks. 
Via The Motley Fool
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
Is the Street's optimism justified here? 
Via The Motley Fool
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M
Via Benzinga
Topics Earnings
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
1 Cathie Wood Stock That Could Double Your Money
This gene-editing pioneer stands out as a top growth stock to buy right now. 
Via The Motley Fool
Cathie Wood's Ark Invest Buys $16M Worth Of Shares Of Flying Taxi Company Archer Aviation — Sells Shopify Stock Worth Millions
Via Benzinga
Cathie Wood's Ark Invest Sells More Tesla Stock — Acquires Shares Of Flying Taxi Company
Via Benzinga
Cathie Wood's Ark Invest Sells $2.15M Of Tesla Shares Despite Own Bullish Projections
Via Benzinga
Cathie Wood's Ark Invest Acquires $5.5M of Robinhood Shares Following Platform's First Profitable Quarter
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These three undervalued biotech stocks could have plenty of room to run if their efforts to push out promising pipeline drugs are successful. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
3 Pharma Stocks That AI is Loving in July
Artificial intelligence recommends that these are the three stocks to consider when investing in pharma stocks. 
Via InvestorPlace
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
What Will Amgen Buy Next?
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Reaching profitability could be harder than investors expect. 
Via The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
3 Monster Stocks in the Making to Buy Right Now
They're not monsters now -- but just give them some time. 
Via The Motley Fool
Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?
Pre-revenue biotechs don't have many ways to juice their share prices. 
Via The Motley Fool
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
There's more than one reason to sell a stock while buying another. 
Via The Motley Fool
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money.
One of these stocks has already doubled this year. 
Via The Motley Fool
Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.
It has quite a few of the core ingredients for success in biopharma. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback